Home Medical Ricoh 3D for Healthcare and SimBioSys develop personalized 3D printed models with...

Ricoh 3D for Healthcare and SimBioSys develop personalized 3D printed models with AI

Ricoh USA and SimBioSys announced a joint initiative to explore cutting-edge technologies that can aid in the treatment of breast cancer. This collaboration aims to explore the potential of artificial intelligence and advanced 3D printing to improve the surgical experience and personalize patient care for breast cancer.

The first AI-generated, 3D-printed breast cancer models will be presented at the upcoming American Society of Breast Surgeons conference. This event will provide a platform to showcase the capabilities and potential of their integrated technologies.

“Through a collaboration with SimBioSys, we hope to not just envision a new future for medical treatment but help actively create it,” said Gary Turner, Managing Director at Ricoh USA, Inc. “Our dedication to precision and personalization in breast cancer care is about to be showcased at ASBrS, reflecting the potential of our combined efforts.”

“Our presence at ASBrS will be an excellent opportunity to demonstrate how this synergy has the potential to benefit surgeons and patients by providing a clearer understanding of complex cancer surgeries before the first incision is made,” said Jyoti Palaniappan, Chief Commercial Officer at SimBioSys.

The technology being presented at the ASBrS conference is currently intended for educational purposes only and is not yet approved by the FDA or any other agency for diagnostic or other purposes. Nevertheless, this initiative underscores the drive to increase precision and personalization in breast cancer treatment through innovative technologies such as AI and 3D printing.

Subscribe to our Newsletter

3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.

Privacy Policy*

You can find the privacy policy for the newsletter here. You can unsubscribe from the newsletter at any time. For further questions, you can contact us here.